文献速递哮喘

症状负担用于描述、预测和预防哮喘发作:随机试验与转化前瞻性研究的患者水平荟萃分析

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.
PubMed 文献 · Lancet Respir Med · 2026-08-20

该患者水平荟萃分析纳入5个数据集共7161名哮喘患者,评估ACQ-5症状负担对未来重度哮喘发作的预测价值及对抗炎治疗反应的影响。

要点

  • ACQ-5症状负担与哮喘临床、生理及炎症特征一致性差,预测重度发作价值有限。
  • 血嗜酸性粒细胞和FeNO比症状更可靠识别高风险及抗炎治疗反应者。

核心结论

  • 症状负担与其他临床、生理或生物特征一致性差,对重度发作预测价值有限。
  • 2型生物标志物更可靠识别高风险患者和治疗反应者。

研究设计与样本

  • 个体参与者数据荟萃分析,纳入随机对照试验和转化前瞻性观察队列研究。
  • 主要分析使用ORACLE2患者水平荟萃分析(n=6513),来自22项随机对照试验的对照组参与者。
  • 额外数据集包括DREAM静脉美泊利珠单抗组(n=461)、严重哮喘横断面队列SA-OT(n=74)及急性哮喘队列PRISMA(n=53)和BOOST(n=60)。
  • 共5个数据集涵盖7161名 distinct 参与者。

主要发现

  • 基线ACQ-5与其他临床、生理或炎症特征无一致横断面关联。
  • 基线ACQ-5未改变DREAM中静脉美泊利珠单抗的相对和绝对发作风险降低。

临床怎么用

  • 症状可能需结合上下文解读以指导哮喘抗炎治疗升级。
  • 2型生物标志物(血嗜酸性粒细胞和FeNO)更可靠识别高风险和可能治疗反应者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma symptoms often guide disease assessment and management, but their prognostic and predictive value is unclear. We evaluated the extent to which symptom burden measured by the 5-item Asthma Control Questionnaire (ACQ-5) predicts future severe asthma attacks and response to anti-inflammatory therapy. METHODS: We conducted an individual participant data meta-analysis of selected randomised controlled trials and translational observational cohort studies of asthma of varying severity. Primary analyses used the ORACLE2 patient-level meta-analysis (n=6513) of control-group participants from 22 randomised controlled trials. Additional datasets from studies assessing type 2 targeting anti-inflammatory therapies were included on the basis of availability of data, to provide insight into the association between ACQ-5 and sputum cell counts or mediator data. Additional datasets were the DREAM intravenous mepolizumab group (n=461); a cross-sectional severe asthma cohort (SA-OT, n=74); and two acute asthma cohorts (PRISMA, biologic-naive, n=53; BOOST, anti-interleukin-5-treated, n=60). Associations between baseline ACQ-5 scores and clinical, physiological, and inflammatory profiles, asthma attack risk, and anti-inflammatory treatment responses were examined. FINDINGS: Across five datasets encompassing 7161 distinct participants, asthma severity, lung function, inflammatory profiles, comorbidities, and ACQ-5 results varied widely. The proportion of patients with high symptom burden (ACQ-5 score >1·5) ranged from 39% to 100%. Baseline ACQ-5 showed no consistent cross-sectional association with other clinical, physiological, or inflammatory asthma features. Each 0·5-point increase in baseline ACQ-5 score was associated with a modest increase in future asthma attack risk (adjusted rate ratio [aRR] 1·09 [95% CI 1·06-1·12]; Δ R2=0·02 vs multivariable prediction model without ACQ-5). Baseline ACQ-5 score did not alter relative and absolute attack risk reduction from intravenous mepolizumab in DREAM. By contrast, patients with high blood eosinophil counts and high fractional exhaled nitric oxide (FeNO) had the highest relative and absolute risk reduction (2·81 vs 1·17 attacks; aRR 0·38 [95% CI 0·25-0·57]). In the PRISMA and BOOST datasets, ACQ-5 was not associated with post-corticosteroid lung function change. Across studies, relative and absolute treatment effects showed consistent associations with blood eosinophil counts and FeNO. INTERPRETATION: In a large, individual patient-level meta-analysis of randomised controlled trials and translational prospective observational cohort studies, we observed little alignment of symptom burden with other clinical, physiological, or biological features of asthma and modest prognostic value for severe attacks. Conversely, type 2 biomarkers more reliably identified patients at high risk and those likely to respond to treatment. Symptoms might require contextual interpretation to guide anti-inflammatory escalation in asthma. FUNDING: National Institute for Health and Care Research, Association Pulmonaire du Québec, Fonds de Recherche du Québec-Santé, and The Academy of Medical Sciences.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Couillard S, Meulmeester FL, Charland P, et al. Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies. Lancet Respir Med. 2026. PMID: 42624803. doi:10.1016/S2213-2600(26)00150-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。